Format

Send to

Choose Destination
Planta Med. 2012 Sep;78(13):1400-15. doi: 10.1055/s-0032-1315145. Epub 2012 Aug 3.

Botanical-drug interactions: a scientific perspective.

Author information

1
Food and Drug Administration Office of Clinical Pharmacology 10903 New Hampshire Avenue Silver Spring, MD 20993, USA. mtoccafondo@yahoo.com

Abstract

There is a continued predisposition of concurrent use of drugs and botanical products. A general lack of knowledge of the interaction potential together with an under-reporting of botanical use poses a challenge for the health care providers and a safety concern for patients. Botanical-drug interactions increase the patient risk, especially with regard to drugs with a narrow therapeutic index (e.g., warfarin, cyclosporine, and digoxin). Examples of case reports and clinical studies evaluating botanical-drug interactions of commonly used botanicals in the US are presented. The potential pharmacokinetic and pharmacodynamic bases of such interactions are discussed, as well as the challenges associated with the interpretation of the available data and prediction of botanical-drug interactions. Recent FDA experiences with botanical products and interactions including labeling implications as a risk management strategy are highlighted.

PMID:
22864989
DOI:
10.1055/s-0032-1315145
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York
Loading ...
Support Center